Granules India net profit rises 71 percent to Rs 164 crore in Q2
New Delhi: Drug firm Granules India on Tuesday reported a 70.82 per cent rise in its consolidated net profit to Rs 163.63 crore for the second quarter ended September 30, mainly on account of robust sales.The company had posted a net profit of Rs 95.79 crore for the corresponding period previous fiscal, Granules India said in a BSE filing.Consolidated revenue from operations stood at Rs...
New Delhi: Drug firm Granules India on Tuesday reported a 70.82 per cent rise in its consolidated net profit to Rs 163.63 crore for the second quarter ended September 30, mainly on account of robust sales.
The company had posted a net profit of Rs 95.79 crore for the corresponding period previous fiscal, Granules India said in a BSE filing.
Consolidated revenue from operations stood at Rs 858.12 crore for the quarter under consideration. It was Rs 699.53 crore in the same period a year ago, it added.
"I am pleased to announce second consecutive robust performance by all our business segments, fuelled the 22.7 per cent growth in Q2FY21 revenues to Rs 858 crore," Granules India Chairman and MD Krishna Prasad Chigurupati said.
Read also: Granules India Dexmethylphenidate HCl ER capsules get USFDA approval to treat ADHD
The company''s Board has declared a second interim dividend of 25 paise per equity share of Re 1 each, the filing said.
Shares of Granules India Ltd were trading at Rs 393.55 per scrip on BSE, up 0.54 per cent from its previous close.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd